126 related articles for article (PubMed ID: 22903691)
21. ECA39 is regulated by c-Myc in human and by a Jun/Fos homolog, Gcn4, in yeast.
Ben-Yosef T; Yanuka O; Benvenisty N
Oncogene; 1996 Nov; 13(9):1859-66. PubMed ID: 8934531
[TBL] [Abstract][Full Text] [Related]
22. c-Myc overexpression promotes a germinal center-like program in Burkitt's lymphoma.
Scheller H; Tobollik S; Kutzera A; Eder M; Unterlehberg J; Pfeil I; Jungnickel B
Oncogene; 2010 Feb; 29(6):888-97. PubMed ID: 19881537
[TBL] [Abstract][Full Text] [Related]
23. Uncoupling of genomic instability and tumorigenesis in a mouse model of Burkitt's lymphoma expressing a conditional box II-deleted Myc protein.
Fest T; Guffei A; Williams G; Silva S; Mai S
Oncogene; 2005 Apr; 24(18):2944-53. PubMed ID: 15735723
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus lytic cycle activation alters proteasome subunit expression in Burkitt's lymphoma cells.
De Leo A; Matusali G; Arena G; Di Renzo L; Mattia E
Biol Chem; 2010 Sep; 391(9):1041-6. PubMed ID: 20536393
[TBL] [Abstract][Full Text] [Related]
25. Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma.
Niklinski J; Claassen G; Meyers C; Gregory MA; Allegra CJ; Kaye FJ; Hann SR; Zajac-Kaye M
Mol Cell Biol; 2000 Jul; 20(14):5276-84. PubMed ID: 10866684
[TBL] [Abstract][Full Text] [Related]
26. Quantitative analysis of CDKN2A methylation, mRNA, and p16(INK4a) protein expression in children and adolescents with Burkitt lymphoma: biological and clinical implications.
Robaina MC; Faccion RS; Arruda VO; de Rezende LM; Vasconcelos GM; Apa AG; Bacchi CE; Klumb CE
Leuk Res; 2015 Feb; 39(2):248-56. PubMed ID: 25542698
[TBL] [Abstract][Full Text] [Related]
27. Molecular biology of Burkitt's lymphoma.
Hecht JL; Aster JC
J Clin Oncol; 2000 Nov; 18(21):3707-21. PubMed ID: 11054444
[TBL] [Abstract][Full Text] [Related]
28. [Detection of translocation t(8;14)(q24;132) in pediatric Burkitt's lymphomas using "long distance" polymerase chain reaction: a new method for diagnosis of Burkitt's lymphomas].
zur Stadt U; Reiter A; Welte K; Sykora KW
Klin Padiatr; 1997; 209(4):165-71. PubMed ID: 9340426
[TBL] [Abstract][Full Text] [Related]
29. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
31. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
32. c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells.
Gavioli R; Frisan T; Vertuani S; Bornkamm GW; Masucci MG
Nat Cell Biol; 2001 Mar; 3(3):283-8. PubMed ID: 11231578
[TBL] [Abstract][Full Text] [Related]
33. Therapeutically promising PNA complementary to a regulatory sequence for c-myc: pharmacokinetics in an animal model of human Burkitt's lymphoma.
Boffa LC; Cutrona G; Cilli M; Mariani MR; Matis S; Pastorino M; Damonte G; Millo E; Roncella S; Ferrarini M
Oligonucleotides; 2005; 15(2):85-93. PubMed ID: 15989423
[TBL] [Abstract][Full Text] [Related]
34. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.
Albert T; Urlbauer B; Kohlhuber F; Hammersen B; Eick D
Oncogene; 1994 Mar; 9(3):759-63. PubMed ID: 8108117
[TBL] [Abstract][Full Text] [Related]
35. Gene-hypermutated isoforms of MYC protein: Tumour-suppressor P-53 protective-initiation of apoptosis that normally prevents Burkitt's lymphoma tumorigenesis can be enhanced.
Wiseman A
Med Hypotheses; 2006; 66(5):1046-7. PubMed ID: 16413684
[No Abstract] [Full Text] [Related]
36. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
[TBL] [Abstract][Full Text] [Related]
37. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
[TBL] [Abstract][Full Text] [Related]
38. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
39. Advances in the understanding of MYC-induced lymphomagenesis.
Klapproth K; Wirth T
Br J Haematol; 2010 May; 149(4):484-97. PubMed ID: 20346013
[TBL] [Abstract][Full Text] [Related]
40. Establishment of the novel B acute lymphoblastic leukemia (FAB L3) cell line KHM-10B with a 13q34 abnormality and constitutive expression of c-myc and max during cell cycle.
Sonoki T; Matsuzaki H; Miyamoto K; Taniwaki M; Yoshino T; Hata H; Yoshida M; Matsuno F; Nagasaki A; Kuribayashi N
Leukemia; 1995 Dec; 9(12):2093-9. PubMed ID: 8609722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
